43 trends tracked about this subject — the full history, oldest to newest below.
Dow Jones futures face pressure as anticipation of a Federal Reserve rate hike coincides with rising oil prices and yields.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.
GSK is advancing a new mRNA flu vaccine to Phase III trials after the candidate outperformed standard vaccinations in earlier testing.
Wall Street closed August with gains driven by an unusual set of winners and a continued recovery within the software industry.
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
FDA clears new Moderna and XFG‑Adapted COVID shots for fall 2026 as cases climb, prompting fresh media focus on seasonal protection.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck have reported a significant triumph regarding a collaborative cancer vaccine trial that could revolutionize oncology treatment.
The FDA has approved Moderna's mRNA-based flu vaccine, marking a shift in immunization technology for older adults.
Advancements in mRNA technology are driving the development of cancer vaccines, specifically targeting melanoma and expanding medical breakthroughs.
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck's mRNA melanoma vaccine is drawing significant attention as a potential game changer according to recent coverage.
Recent trial results for an mRNA vaccine developed by Moderna point toward a potential shift in future cancer care.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna shares double following clinical trial results for a personalized mRNA melanoma vaccine developed with Merck.
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
Health authorities and global outlets report ongoing rollout discussions and upcoming trials for Ebola vaccines in the DRC.
The U.S. has approved the first-ever mRNA flu vaccine from Moderna, though concerns over side effects may impact public adoption.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna launches its first human trial for a new mRNA Ebola vaccine targeting the specific strain spreading in the Democratic Republic of Congo.
12 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An FDA advisory committee has unanimously recommended the approval of Moderna's mRNA influenza vaccine for older adults.
An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
Global research efforts accelerate as scientists scramble to test new vaccines and treatments in response to a widening Ebola outbreak.